NASDAQ:GLYC

GlycoMimetics Stock Forecast, Price & News

$2.20
+0.09 (+4.27 %)
(As of 09/21/2021 12:10 PM ET)
Add
Compare
Today's Range
$2.14
$2.22
50-Day Range
$1.80
$2.34
52-Week Range
$1.78
$4.40
Volume1,385 shs
Average Volume683,539 shs
Market Capitalization$113.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
30 days | 90 days | 365 days | Advanced Chart
Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.


GlycoMimetics logo

About GlycoMimetics

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

464th out of 1,352 stocks

Pharmaceutical Preparations Industry

225th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

Is GlycoMimetics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GlycoMimetics stock.
View analyst ratings for GlycoMimetics
or view top-rated stocks.

What stocks does MarketBeat like better than GlycoMimetics?

Wall Street analysts have given GlycoMimetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlycoMimetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GlycoMimetics?

GlycoMimetics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,100,000 shares, a drop of 28.6% from the August 15th total of 1,540,000 shares. Based on an average daily trading volume, of 460,600 shares, the short-interest ratio is currently 2.4 days. Approximately 2.7% of the company's stock are sold short.
View GlycoMimetics' Short Interest
.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for GlycoMimetics
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) released its earnings results on Thursday, August, 5th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.03.
View GlycoMimetics' earnings history
.

How has GlycoMimetics' stock price been impacted by Coronavirus?

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLYC shares have decreased by 26.9% and is now trading at $2.15.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GLYC?

3 brokers have issued 1 year price targets for GlycoMimetics' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate GlycoMimetics' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 458.1% from the stock's current price.
View analysts' price targets for GlycoMimetics
or view top-rated stocks among Wall Street analysts.

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the following people:
  • Harout Semerjian, President, Chief Executive Officer & Director
  • Brian M. Hahn, Chief Financial Officer & Senior Vice President
  • John L. Magnani, Chief Scientific Officer & Senior VP-Research
  • Henry Flanner, Vice President-Technical Operations
  • Eric Feldman, Chief Medical Officer & Senior Vice President

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.41%), Dimensional Fund Advisors LP (2.29%), BlackRock Inc. (1.72%), Renaissance Technologies LLC (1.47%), Millennium Management LLC (1.33%) and Geode Capital Management LLC (0.68%). Company insiders that own GlycoMimetics stock include Bvf Partners L P/Il and Daniel M Junius.
View institutional ownership trends for GlycoMimetics
.

Which major investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Northern Trust Corp, Morgan Stanley, Morgan Stanley, and AQR Capital Management LLC.
View insider buying and selling activity for GlycoMimetics
or view top insider-selling stocks.

Which major investors are buying GlycoMimetics stock?

GLYC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Tibra Equities Europe Ltd, Renaissance Technologies LLC, Susquehanna Fundamental Investments LLC, Goldman Sachs Group Inc., QS Investors LLC, and XTX Topco Ltd. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius.
View insider buying and selling activity for GlycoMimetics
or or view top insider-buying stocks.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $2.15.

How much money does GlycoMimetics make?

GlycoMimetics has a market capitalization of $110.81 million and generates $10.16 million in revenue each year. The biotechnology company earns $-51,030,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How many employees does GlycoMimetics have?

GlycoMimetics employs 54 workers across the globe.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is www.glycomimetics.com.

Where are GlycoMimetics' headquarters?

GlycoMimetics is headquartered at 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 243-1201 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.